Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 14, 2026, Aardvark Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). Of the 21,884,158 shares of the Company's common stock outstanding as of June 18, 2026, the record date for the Annual Meeting, 11,992,479 shares were represented at the Annual Meeting virtually or by proxy, constituting approximately 54.79% of the outstanding shares entitled to vote and constituting a quorum for the transaction of business.

At the Annual Meeting, the Company's stockholders considered three proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on July 10, 2026 (the "Proxy Statement").

Set forth below is a brief description of each proposal voted upon at the Annual Meeting and the voting results with respect to each proposal.

Proposal No. 1. To elect two Class I directors to hold office until the Company's 2029 annual meeting of stockholders or until their successors are elected and qualified:

As a result, the Company's stockholders voted to elect Victor Tong, Jr. and Jeffrey Chi, Ph.D. as Class I directors to serve until the Company's 2029 annual meeting of stockholders or until his respective successor is duly elected and qualified.

Proposal No. 2. To ratify the appointment by the Audit Committee of the Company's Board of Directors of BDO USA, P.C. as the independent registered public accounting firm and independent auditor of the Company for the year ending December 31, 2026:

As a result, the Company's stockholders voted to ratify the appointment by the Audit Committee of the Company's Board of Directors of BDO USA, P.C. as the independent registered public accounting firm and independent auditor of the Company for the year ending December 31, 2026.

Proposal No. 3. To approve the repricing of certain outstanding stock options issued under the Aardvark Therapeutics, Inc. 2017 Equity Incentive Plan, as amended (the "2017 Plan"), the Aardvark Therapeutics, Inc. 2025 Equity Incentive Plan (the "2025 Plan") and the Aardvark Therapeutics, Inc. 2025 Inducement Equity Incentive Plan (the "2025 Inducement Plan") that are held by Eligible Participants (as defined in the Proxy Statement) of the Company:

As a result, the Company's stockholders voted to approve the repricing of certain outstanding stock options issued under the 2017 Plan, the 2025 Plan and the 2025 Inducement Plan that are held by Eligible Participants of the Company.